Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety

A lower dose of capecitabine revealed better toxicity profiles and comparable efficacy in treatment of metastatic breast cancer (MBC). We aimed to evaluate the efficacy and toxicity of lower dose of capecitabine in comparison with the standard dose.

Bibliographic Details
Main Authors:	Aboelnaga Engy M, El-beshbishi Wafaa
Format:	Article
Language:	English
Published:	Sciendo 2021-08-01
Series:	Forum of Clinical Oncology
Subjects:	capecitabine metastatic breast cancer low dose standard dose efficacy safety
Online Access:	https://doi.org/10.2478/fco-2019-0015

id	doaj-45a667e612aa40d6aab14545b6767183
record_format	Article
spelling	doaj-45a667e612aa40d6aab14545b67671832021-10-03T07:42:46ZengSciendoForum of Clinical Oncology1792-362X2021-08-01121122110.2478/fco-2019-0015Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safetyAboelnaga Engy M0El-beshbishi Wafaa1Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University, EgyptClinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University, EgyptA lower dose of capecitabine revealed better toxicity profiles and comparable efficacy in treatment of metastatic breast cancer (MBC). We aimed to evaluate the efficacy and toxicity of lower dose of capecitabine in comparison with the standard dose.https://doi.org/10.2478/fco-2019-0015capecitabinemetastatic breast cancerlow dosestandard doseefficacysafety
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Aboelnaga Engy M El-beshbishi Wafaa
spellingShingle	Aboelnaga Engy M El-beshbishi Wafaa Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety Forum of Clinical Oncology capecitabine metastatic breast cancer low dose standard dose efficacy safety
author_facet	Aboelnaga Engy M El-beshbishi Wafaa
author_sort	Aboelnaga Engy M
title	Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety
title_short	Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety
title_full	Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety
title_fullStr	Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety
title_full_unstemmed	Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety
title_sort	comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: efficacy and safety
publisher	Sciendo
series	Forum of Clinical Oncology
issn	1792-362X
publishDate	2021-08-01
description	A lower dose of capecitabine revealed better toxicity profiles and comparable efficacy in treatment of metastatic breast cancer (MBC). We aimed to evaluate the efficacy and toxicity of lower dose of capecitabine in comparison with the standard dose.
topic	capecitabine metastatic breast cancer low dose standard dose efficacy safety
url	https://doi.org/10.2478/fco-2019-0015
work_keys_str_mv	AT aboelnagaengym comparativestudyoflowdoseofcapecitabineversusstandarddoseinmetastaticbreastcancerefficacyandsafety AT elbeshbishiwafaa comparativestudyoflowdoseofcapecitabineversusstandarddoseinmetastaticbreastcancerefficacyandsafety
_version_	1716845723672117248

Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety

Similar Items